A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma
JS Weber, FL Hua, L Spears, V Marty… - Journal of …, 1999 - journals.lww.com
Cytolytic and helper T cells recognize small peptide fragments of protein antigens that are
intracellularly processed and delivered to the cell surface in conjunction with HLA
molecules. In mice, peptide vaccines can protect against lethal virus infections and tumor
challenges. To test whether epitope peptides derived from a human tumor antigen can
induce immune responses in patients, a vaccine was prepared consisting of an HLA-A1-
restricted epitope of the antigen MAGE-3 mixed with a pan-class II epitope peptide PADRE …
intracellularly processed and delivered to the cell surface in conjunction with HLA
molecules. In mice, peptide vaccines can protect against lethal virus infections and tumor
challenges. To test whether epitope peptides derived from a human tumor antigen can
induce immune responses in patients, a vaccine was prepared consisting of an HLA-A1-
restricted epitope of the antigen MAGE-3 mixed with a pan-class II epitope peptide PADRE …